What we do RPG Life Sciences is an integrated pharmaceutical company manufacturing and marketing formulations and active pharmaceutical ingredients in domestic and international markets. |
Founded in 1,968 |
Market share Leader in immunosuppressants and significant presence in cardiovascular, diabetology, oncology, and other specialty therapies, serving 50+ markets. |
Problem solved Provides critical medications across chronic and specialty therapeutic areas addressing patient needs in immunosuppressants, oncology, cardiology, and more. |
Top clients or who we serve Serves doctors, hospitals, and pharmaceutical companies globally, with B2B and B2C operations in regulated and emerging markets. |
Key management - |
Our journey and innovations Started as Searle India joint venture; expanded through acquisitions, product launches across key therapy areas, and global manufacturing certifications. |
Where we operate Operates in India, Nepal, UK, Australia, Canada, Africa, Middle East, Southeast Asia, and Latin America. |
Top products or what we offer Offers branded and generic formulations in immunosuppressants, oncology, cardiology, APIs like Azathioprine, Naprosyn, and emerging biosimilars. |
Top brands Azoran, Aldactone, Lomotil, Naprosyn, Seretane, Darba, XMAB, Siloxogene - strong legacy and growing specialty brands. |
Raw materials needed Specialty chemicals and intermediates for APIs and formulations manufacturing. |
Raw materials supplier Not specified, likely includes global and domestic chemical suppliers. |
Recurring vs cyclical contribution Revenue largely recurring from chronic specialty drug sales with growth from new launches. |
Our industry position Among top Indian pharmaceutical firms with strong foothold in immunosuppressants and expanding global generics. |
Financial highlights FY25 Revenue Rs. 666.11 Cr, Profit after tax Rs. 183.24 Cr, consistent growth over prior years. |
Geographical revenue split India contributes ~65%, international markets ~35% of revenues. |
Order book - |
Whats driving growth New product launches, geographic expansion, specialty portfolio growth, and digital engagement platforms. |
Our future plans Investing in capacity expansion, product pipeline in specialty therapies, digital transformation, and strategic acquisitions. |
Our green promise Committed to ESG, energy conservation, safety audits, and sustainable practices guided by RPG Foundation. |
Our people and values 1300+ employees fostering a performance-focused, inclusive culture with training and development initiatives. |
Key challenges ahead Managing regulatory compliances, competitive generics market, and supply chain resilience. |
Interesting facts One of the few Indian pharma firms with WHO, EU GMP, PMDA Japan, and TGA Australia certifications. |
Risks and strategy Mitigates risks via diversification, product portfolio innovation, and robust quality and compliance systems. |
